Search the Newsreel

ANVS: Alzheimer's Phase 3 trial fully enrolled; R&D costs and net loss per share increased year-over-year

Annovis Bio (ANVS) has fully enrolled its pivotal Alzheimer's Phase 3 trial, with topline data anticipated in Q1 2027. The company experienced a sharp increase in research and development expenses, leading to a higher net loss per share year-over-year. Additionally, enrollment continues for the …

Highbridge Capital (ANVS) discloses 6.1% Annovis Bio stake tied to 2.78M warrant shares

Highbridge Capital Management, LLC has disclosed a beneficial ownership of 6.1% in Annovis Bio, Inc., which is tied to 2,775,578 shares of common stock issuable upon the exercise of warrants. This stake is calculated based on 42,541,868 outstanding common shares after a referenced offering …

Annovis Bio Sees Unusually Large Options Volume (NYSE:ANVS)

Annovis Bio (NYSE:ANVS) experienced unusual options trading volume on Friday, with traders buying 3,595 put options, a 139% increase over its typical daily volume. Despite a "Moderate Buy" consensus rating from analysts, the stock is trading near its 52-week low. The company recently reported …

Annovis expects October study to let Alzheimer’s patients continue treatment

Annovis (NYSE: ANVS) reported Q2 2026 results, highlighting that its pivotal Phase 3 early Alzheimer’s trial is fully enrolled with 850 patients and an open-label extension for Alzheimer's patients is planned for October 2026. The company also provided updates on its Parkinson's open-label extension, …

Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results

Annovis Bio, Inc. announced significant clinical advancements and its second-quarter 2026 financial results. The company has fully enrolled its pivotal Phase 3 Alzheimer's disease trial with 850 patients, exceeding original projections, and is progressing with its Parkinson's disease open-label extension study. Annovis plans to …

Annovis Bio Inc (ANVS) Stock News Today

Annovis Bio Inc expected to post a loss of 45 cents a share - Earnings Preview

Annovis Bio Inc (ANVS) is projected to report a loss of 45 cents per share, according to this earnings preview. The article, sourced from Refinitiv via TradingView News, indicates this financial expectation for the company. Readers can access further details on TradingView.

Annovis Bio Inc (ANVS) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for Annovis Bio Inc (ANVS), highlighting a "Buy" rating based on three analysts, with a target price of USD 12.60 representing a 577.42% upside. It details past and future EPS expectations, noting the previous quarter's EPS beat market …

Annovis Bio (ANVS) Projected to Post Quarterly Earnings on Tuesday

Annovis Bio (ANVS) is expected to report its Q2 2026 earnings before market open on Tuesday, August 11th, with analysts forecasting a loss of $0.44 per share. The company previously missed estimates with a $0.63 per share loss. Despite recent trading near its 52-week …

ETFs Investing in Annovis Bio Inc Stocks

This article identifies ETFs that hold Annovis Bio Inc (ANVS) stocks. It provides a list of funds, including the BUSM EA Bridgeway Ultra-Small Company Market ETF, along with their market value, weight, issuer, management style, and expense ratio. The information aims to help investors …

Annovis Bio (ANVS): Empery Asset Management discloses 5.64% beneficial stake

Empery Asset Management, LP and Ryan M. Lane have disclosed a 5.64% beneficial ownership stake in Annovis Bio, Inc. (ANVS) through a Schedule 13G filing. They report control over 2,401,476 shares of common stock, representing this percentage based on 42,541,868 shares outstanding as of …

Annovis Bio Inc (ANVS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article discusses the revenue breakdown of Annovis Bio Inc (ANVS), noting that relevant data regarding business segments and regional revenue and profit contribution have not been disclosed by the company. It highlights the current stock information for ANVS, including its market cap and …

Annovis Bio Inc (ANVS) Institutional Confidence

This article from TradingKey focuses on the institutional confidence in Annovis Bio Inc (ANVS). It presents a table detailing significant institutional shareholders and the changes in their holdings, highlighting key investors like Hoffman (Michael B), Maccecchini (Maria-Luisa), and Heights Capital Management. The data shows …

Annovis Bio Inc (ANVS) Cash Flow

This article provides a detailed cash flow statement for Annovis Bio Inc (ANVS), covering quarterly and annual data for operating, investing, and financing activities. It includes key figures such as net income from continuing operations and changes in working capital, allowing users to evaluate …

Annovis Bio Inc (ANVS) Financial Health: Profitability & Balance Sheet Analysis

This article provides an overview of Annovis Bio Inc (ANVS), focusing on its financial health. It includes basic stock information such as its current price, market cap, and daily change. The content also notes that it offers financial analysis and company overview sections.

Annovis Bio Inc (ANVS) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Annovis Bio Inc's (ANVS) dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years and indicates no available data for specific dividend dates. The article also includes current …

Annovis Bio Inc (ANVS) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Annovis Bio Inc (ANVS), highlighting its current stock price and market capitalization. It notes that key valuation metrics like P/E, P/B, and P/CF ratios have not been disclosed by the company. The analysis is part of a …

ANVS|Annovis Bio Inc|Price:1.650|Chg%:-0.100

Annovis Bio Inc. (ANVS) is a late-stage clinical drug platform company focused on neurodegenerative diseases like Alzheimer's and Parkinson's. Their lead product candidate, Buntanetap, is an orally administered compound for these conditions, while ANVS405 is an intravenous drug for acute brain trauma and stroke, …